Teva Pharmaceutical Industries (TEVA) Shares Outstanding (2009 - 2026)
Teva Pharmaceutical Industries (TEVA) posted Shares Outstanding (Entity) of $1.3 billion for Q1 2026, down 2.23% on a QoQ basis from $1.3 billion in Q4 2025, and up 1.44% year-over-year from $1.3 billion in Q1 2025.
Teva Pharmaceutical Industries (TEVA) Shares Outstanding (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries' Shares Outstanding (Entity) history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 1.44% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 1.44% YoY) and the FY2025 annual result came in at $1.3 billion, up 8.33% from the prior year.
- Shares Outstanding (Entity) was $1.3 billion for Q1 2026 at Teva Pharmaceutical Industries, down from $1.3 billion in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $1.3 billion in Q4 2025 and bottomed at $1.1 billion in Q2 2022.
- A 5-year average of $1.2 billion and a median of $1.2 billion in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) retreated 8.19% — and 2023, when it advanced 10.54%.
- Teva Pharmaceutical Industries' Shares Outstanding (Entity) stood at $1.2 billion in 2022, then changed by 0.0% to $1.2 billion in 2023, then changed by 0.0% to $1.2 billion in 2024, then increased by 8.33% to $1.3 billion in 2025, then fell by 2.23% to $1.3 billion in 2026.
- Business Quant data shows TEVA's Shares Outstanding (Entity) at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 8.98 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 1.16 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 422.10 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 43.50 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 31.59 Bn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 100.50 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 497.70 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 1.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.16 Bn |
| Dec 31, 2025 | 1.15 Bn |
| Sep 30, 2025 | 1.15 Bn |
| Jun 30, 2025 | 1.15 Bn |
| Mar 31, 2025 | 1.14 Bn |
| Dec 31, 2024 | 1.13 Bn |
| Sep 30, 2024 | 1.13 Bn |
| Jun 30, 2024 | 1.13 Bn |
| Mar 31, 2024 | 1.12 Bn |
| Dec 31, 2023 | 1.12 Bn |
| Sep 30, 2023 | 1.12 Bn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 1.12 Bn |
| Dec 31, 2022 | 1.11 Bn |
| Sep 30, 2022 | 1.11 Bn |
| Jun 30, 2022 | 1.11 Bn |
| Mar 31, 2022 | 1.11 Bn |
| Dec 31, 2021 | 1.10 Bn |
| Sep 30, 2021 | 1.10 Bn |
| Jun 30, 2021 | 1.10 Bn |